Cite
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
MLA
Wu, Zhaozhen, et al. “Efficacy and Safety of Anti-PD-1-Based Therapy in Combination with PARP Inhibitors for Patients with Advanced Solid Tumors in a Real-World Setting.” Cancer Immunology, Immunotherapy, vol. 70, no. 10, Oct. 2021, pp. 2971–80. EBSCOhost, https://doi.org/10.1007/s00262-021-02852-4.
APA
Wu, Z., Tao, H., Zhang, S., Wang, X., Ma, J., Li, R., Liu, Z., Wang, J., Cui, P., Chen, S., Di, H., Huang, Z., Zheng, X., & Hu, Y. (2021). Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. Cancer Immunology, Immunotherapy, 70(10), 2971–2980. https://doi.org/10.1007/s00262-021-02852-4
Chicago
Wu, Zhaozhen, Haitao Tao, Sujie Zhang, Xiao Wang, Junxun Ma, Ruixin Li, Zhefeng Liu, et al. 2021. “Efficacy and Safety of Anti-PD-1-Based Therapy in Combination with PARP Inhibitors for Patients with Advanced Solid Tumors in a Real-World Setting.” Cancer Immunology, Immunotherapy 70 (10): 2971–80. doi:10.1007/s00262-021-02852-4.